[{"orgOrder":0,"company":"Evgen Pharma","sponsor":"University of Dundee","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sulforaphane","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ University of Dundee","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ University of Dundee"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Sulforaphane","moa":"SHP2 pathway","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"ACX","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"}]

Find Clinical Drug Pipeline Developments & Deals for .alpha.-Cyclodextrin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lindus Health

                          Country arrow
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Lindus Health

                          Country arrow
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The collaboration aims to conduct the clinical development of ACX, which is evaluating their topical cream's ability to treat patients with moderate to severe inflammatory acne.

                          Brand Name : ACX

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 16, 2024

                          Lead Product(s) : Alpha-Cyclodextrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Acinonyx Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.

                          Brand Name : SFX-01

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 02, 2021

                          Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $15.3 million

                          Deal Type : Public Offering

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.

                          Brand Name : SFX-01

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 19, 2021

                          Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : University of Dundee

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank